Plasma GFAP levels, more accurately than those in CSF, have been shown to distinguish patients with underlying amyloid pathology independently from the severity of cognitive impairment and even in patients with a primary alternative neurodegenerative disorder, such as Lewy Body disease [12,13,14,23]. Here, GFAP is linked to Lewy body dementia.